A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms have changed throughout the study

NCT Number	NCT06693531
Lead Sponsor	Regeneron Pharmaceuticals Collaborators: Sanofi
Conditions	Eosinophilic Esophagitis (EoE)
Enrollment	368 participants
Start Date	2024-11-22
Primary Completion	2030-05-22 (estimated)
Study Completion	2030-05-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-12